Money laundering case: ED custody of Sterling Biotech's director extended till Feb 7

Published On 2018-01-30 04:45 GMT   |   Update On 2018-01-30 04:45 GMT

New Delhi: A Delhi court has extended till February 7 the Enforcement Directorate custody of a director of a Gujarat-based pharma firm in a money laundering case related to a Rs 5,000-crore bank fraud case.


Additional Sessions Judge Sidharth Sharma extended the custody of Rajbhushan Omprakash Dixit, a director of Sterling Biotech, after special public prosecutor Nitesh Rana, appearing for the ED, said his further custodial interrogation was required by the agency.


Read also: Money laundering case: Sterling Biotech’s director arrested sent to ED custody


Rana told the court that the accused, arrested on January 25, is to be confronted with various documents and co-accused to unearth the larger conspiracy.


This is the third arrest in the case. The agency arrested a former director of Andhra Bank, Anup Prakash Garg earlier this month, and a Delhi-based businessman Gagan Dhawan in November last year.


While Garg is currently in judicial custody, Dhawan was granted bail on January 4. All three were arrested under the Prevention of Money Laundering Act (PMLA).


They were named as accused in the cases by the ED and the CBI.


The ED had registered a money laundering case after taking cognizance of a CBI FIR.


The CBI had booked Sterling Biotech, its directors Rajbhushan, Chetan Jayantilal Sandesara, Chetan Sandesara, Nitin Jayantilal Sandesara and Vilas Joshi, chartered accountant Hemant Hathi, Garg and some unidentified persons in connection with the bank fraud case.


It had alleged that the company had taken loans of over Rs 5,000 crore from a consortium led by Andhra Bank which had turned into non-performing assets.


The FIR had also alleged that the total pending dues of the group companies were Rs 5,383 crore as on December 31, 2016.

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News